Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Ascendis Pharma A (ASND) Receivables - Net (2016 - 2025)

Ascendis Pharma A's Receivables - Net history spans 8 years, with the latest figure at $38.6 million for Q4 2023.

  • For Q4 2023, Receivables - Net rose 217.65% year-over-year to $38.6 million; the TTM value through Dec 2023 reached $38.6 million, up 217.65%, while the annual FY2023 figure was $38.8 million, 209.14% up from the prior year.
  • Receivables - Net for Q4 2023 was $38.6 million at Ascendis Pharma A, up from $12.2 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $38.6 million in Q4 2023 and bottomed at $461416.2 in Q4 2020.
  • The 5-year median for Receivables - Net is $2.5 million (2021), against an average of $10.9 million.
  • The largest annual shift saw Receivables - Net soared 12894.87% in 2019 before it plummeted 48.15% in 2020.
  • A 5-year view of Receivables - Net shows it stood at $889937.7 in 2019, then tumbled by 48.15% to $461416.2 in 2020, then soared by 445.44% to $2.5 million in 2021, then skyrocketed by 382.81% to $12.2 million in 2022, then skyrocketed by 217.65% to $38.6 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Receivables - Net are $38.6 million (Q4 2023), $12.2 million (Q4 2022), and $2.5 million (Q4 2021).